CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 1,640 enrolled
Drug / intervention
montelukast sodium +3 moredrug
Likely dose
montelukast sodium 10 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00284856
NCT00284856Phase 3Completed

A Multicenter, Randomized, Double-Blind, Parallel-Group 6-Month Study to Evaluate the Efficacy and Safety of Oral Montelukast Sodium, Fluticasone Propionate and Placebo in Patients With Chronic Asthma Who Smoke Cigarettes

Organon and Co·interventional·Posted Feb 1, 2006·Updated May 10, 2024

In Brief

A Phase 3 clinical trial evaluating montelukast sodium, Comparator: Placebo, and 1 other intervention for Asthma. Completed, enrolled 1,640 participants.

Detailed Summary

This is a multicenter study to evaluate the efficacy and safety of MK0476 versus placebo in participants with chronic asthma who actively smoke cigarettes.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAsthma
Countries--
Collaborators--

Timeline

Phase 3CompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedFeb 1, 2006
Enrollment StartMay 1, 2006
Primary CompletionApr 1, 2010
TodayJul 2, 2026
Enrollment to primary: 3.9 yearsPosted 20.4 years ago

Interventions

montelukast sodiumdrug

montelukast 10 mg tablet once daily, 6 month treatment period

Comparator: Placebodrug

fluticasone propionate 250 mcg Placebo (Pbo) twice daily, 6 month treatment period

Comparator: fluticasonedrug

fluticasone propionate 250 mcg twice daily, 6 month treatment period

Comparator: Placebodrug

montelukast 10 mg Pbo tablet once daily, 6 month treatment period